Menu

Organoid Biobank

From the tissue of numerous colon cancer patients, researchers build 3-D cultures of tumors.

May 11, 2015
Kerry Grens

VAN DE WETERING ET AL./CELL 2015To more faithfully recapitulate cancers in the lab, researchers have built upon existing methods for creating three-dimensional intestines in a dish to grow these so-called organoids out of tumor samples. The scientists used tissue from 20 colorectal cancer patients to create 22 tumor-derived organoids and 19 organoids from the patients’ normal intestinal tissue.

“This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors,” study coauthor Mathew Garnett, a geneticist at the Wellcome Trust Sanger Institute, said in a press release. “We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments.”

Currently, cells lines and xenotransplantation of tumors into mice are the best methods for studying cancers in the laboratory. But cell lines offer only a short-term glimpse of the cancer, and mouse models can be resource-intensive, the authors wrote in their report, published in Cell last week (May 7).

Garnett and his colleagues analyzed genetic mutations of the cancerous organoids, finding them similar to the original tumors. “They capture most if not all of the most important mutations,” Eduard Batlle at the Institute for Research in Biomedicine in Barcelona, Spain, who was not part of the study told Science News. Then the team used the organoids to screen 83 drugs, finding the tumor cultures responded as would be expected based on their genetic profiles.

“Here, we demonstrate that the organoid culture platform can be exploited for genomic and functional studies at the level of the individual patient at a scale that cannot be achieved by existing approaches,” the authors wrote.

According to Science News, two clinical trials are already taking advantage of tumor-derived organoids. One is examining how well organoids can predict a patient’s response to a drug, and the other will look at potential treatments for patients with a cancer that has spread in the body.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening